We previously demonstrated in a mouse model of NASH that liver LECs have increased expression of VEGFR-2 transcript and treatment of NASH mice with rVEGF-C (cys156ser), to induce signaling through VEGFR-3, improved lymphatic drainage from the liver (Burchill et al., 2021). This evidence concerns the gene FLT4 and metabolic dysfunction-associated steatohepatitis.